These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4725930)

  • 21. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure.
    van den Berg DT; de Kloet ER; van Dijken HH; de Jong W
    Endocrinology; 1990 Jan; 126(1):118-24. PubMed ID: 2293978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A structure-activity relationship study of spirolactones. Contribution of the cyclopropane ring to antimineralocorticoid activity.
    Chinn LJ; Salamon KW; Desai BN
    J Med Chem; 1981 Sep; 24(9):1103-7. PubMed ID: 6270335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MINERALOCORTICOID-BLOCKING PROPERTIES OF A PROGESTERONE-LIKE DERIVATIVE (SC-11835).
    KAGAWA CM
    Endocrinology; 1964 May; 74():724-30. PubMed ID: 14168560
    [No Abstract]   [Full Text] [Related]  

  • 25. Synthesis of 15-keto-6beta, 7beta-methyleneprogesterone. Effect of the 6beta, 7beta-methylene group on mineralocorticoid activity.
    Chinn LJ; Desai BN
    J Med Chem; 1975 Mar; 18(3):268-71. PubMed ID: 1133817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats.
    Brandish PE; Chen H; Szczerba P; Hershey JC
    J Pharmacol Toxicol Methods; 2008; 57(2):155-60. PubMed ID: 18304838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
    Sica DA
    Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mineralocorticoids and sweat gland function.
    Gibiński K; Giec L; Nowak S; Kokot F
    Acta Biol Med Ger; 1970; 25(1):201-5. PubMed ID: 5489678
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.
    McInnes GT; Shelton JR; Harrison IR; Perkins RM; Palmer RF
    Br J Clin Pharmacol; 1982 Feb; 13(2):187-94. PubMed ID: 7059416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of antialdosterone activity in adrenalectomized dogs.
    Hershberger LG; Thompson CR
    Proc Soc Exp Biol Med; 1968 Oct; 129(1):24-6. PubMed ID: 5686523
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 32. Diuretic, natriuretic and kaliuretic effects of dexamethasone.
    Paixão AD; Figueiredo BC; Gurgel Mendes MF; Fonteles MC
    Braz J Med Biol Res; 1989; 22(8):1001-4. PubMed ID: 2633840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 34. New mineralocorticoids: 5alpha-dihydroaldosterone and 5alpha-dihydro-11-deoxycorticosterone.
    Sekihara H; Island DP; Liddle GW
    Endocrinology; 1978 Oct; 103(4):1450-2. PubMed ID: 744157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal inactivation, mineralocorticoid generation, and 11beta-hydroxysteroid dehydrogenase inhibition ameliorate the antimineralocorticoid effect of progesterone in vivo.
    Quinkler M; Meyer B; Oelkers W; Diederich S
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3767-72. PubMed ID: 12915667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mechanism of mineralocorticoid action of carbenoxolone.
    Armanini D; Karbowiak I; Krozowski Z; Funder JW; Adam WR
    Endocrinology; 1982 Nov; 111(5):1683-6. PubMed ID: 6290195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions of spironolactone and hydrochlorothiazide with aspirin in the rat and dog.
    Hofmann LM; Krupnick MI; Garcia HA
    J Pharmacol Exp Ther; 1972 Jan; 180(1):1-5. PubMed ID: 5010414
    [No Abstract]   [Full Text] [Related]  

  • 38. Difference of in vivo and in vitro antimineralocorticoid potency of progesterone.
    Quinkler M; Diederich S
    Endocr Res; 2002 Nov; 28(4):465-70. PubMed ID: 12530650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
    Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular and renal effects of central administration of a mineralocorticoid receptor antagonist in conscious female rats.
    Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
    Eur J Pharmacol; 1999 Dec; 385(2-3):199-202. PubMed ID: 10607876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.